Invivyd IVVD
NASDAQ IVVD
$0.83 +0.00 (+0.00%)
At close: Sep 4, 2026 · 4:00 PM EDT

Invivyd (IVVD) Cash from Financing Activities (2021 - 2025)

Invivyd's (IVVD) quarterly Cash from Financing Activities came in at $157.2 million in Q4 2025, up 204025.97% on a YoY basis from N/an in Q4 2024, and up 169.54% quarter-over-quarter from $58.3 million in Q3 2025.

Analysis

Invivyd (IVVD) Cash from Financing Activities (2021 - 2025) Analysis & Trends

Invivyd (IVVD) has reported Cash from Financing Activities for 5 consecutive years, with $157.2 million the latest figure, recorded in Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 204025.97% year-over-year to $157.2 million; the trailing twelve-month figure through Dec 2025 stood at $215.6 million (up 448.24% YoY), and the FY2025 full-year result was $215.6 million, up 448.24% from the prior year.
  • Cash from Financing Activities improved to $157.2 million in Q4 2025 per IVVD's latest filing, from $58.3 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $334.8 million in Q2 2021 and bottomed at -$749000.0 in Q4 2021.
  • Historically, Cash from Financing Activities has averaged $48.4 million across 5 years, with a median of $141000.0 in 2022.
  • The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities sank 99.98% in 2022, then surged 204025.97% in 2025.
  • Over 5 years, Cash from Financing Activities stood at -$749000.0 in 2021, then jumped by 118.83% to $141000.0 in 2022, then changed by 0.0% to $141000.0 in 2023, then slumped by 45.39% to $77000.0 in 2024, then soared by 204025.97% to $157.2 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods registered $157.2 million, $58.3 million, and $131000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn -1.48 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn 2.34 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn -426.70 Mn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn -1.22 Bn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn -
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn 14.00 Mn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn 36.24 Mn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn 1.30 Bn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn 27.18 Mn
10 Invivyd 244.65 Mn 84.57 Mn 13.01 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 157.18 Mn
Sep 30, 2025 58.31 Mn
Jun 30, 2025 131,000.00
Mar 31, 2025 10,000.00
Dec 31, 2024 77,000.00
Sep 30, 2024 61,000.00
Jun 30, 2024 92,000.00
Mar 31, 2024 39.10 Mn
Dec 31, 2023 141,000.00
Sep 30, 2023 92,000.00
Jun 30, 2023 270,000.00
Mar 31, 2023 542,000.00
Dec 31, 2022 141,000.00
Sep 30, 2022 246,000.00
Jun 30, 2022 74,000.00
Mar 31, 2022 45,000.00
Dec 31, 2021 -749,000.00
Sep 30, 2021 328.60 Mn
Jun 30, 2021 334.83 Mn